A Safety Study of SGN-CD33A in AML Patients

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2016 by Seattle Genetics, Inc.
Sponsor:
Information provided by (Responsible Party):
Seattle Genetics, Inc.
ClinicalTrials.gov Identifier:
NCT01902329
First received: July 15, 2013
Last updated: January 28, 2016
Last verified: January 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2017
  Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)